FDA has declared their
endorsement of a new Pfizer Inc.(NYSE:PFE) drug as an authentic antidote for
treatment of rare group of blood cancer as they have certified this medicine
effective for treatment of a rare group of bone marrow and blood cancer
disease. The name of the drug is Bosulif.
Research and study on
the administration on Bosulif has revealed the fact this daily pill can
effectively treat chronic myeloid leukemia; in this carcinogenic disease
patients becomes career of a specific genetic variation. Mainly senior people
are affected by this type of blood cancer where bone marrow becomes an
unhealthy producer of white cells which cause problem for normal cells to grow
resulting in weak immunity power of the patient. Administration of Bosulif can
block an enzyme named tyrosine kinase, which is known as a trigger for mass
production of these unhealthy white cells. Dumping of these harful white blood
cells are extremely harmful for elimination of cancer related complications.
Get Free Trend Analysis On PFE
FDA has recommended
Bosulif for the patients who are non-responsive toward general cancer therapies
including Novartis' Gleevec as well as for those cancer patients having genetic
mutation related disorder called Philadelphia chromosome. The percentage for
this patients are 15% out of blood cancer disease but these patients are found
non responsive to drug treatments so far, with Bosulif there is a possibility
of their physical improvement, FDA has recommended.
According to FDA
statistics, almost 5,430 patients will be diagnosed with chronic myelogenous
leukemia by this current year; as per the Pfizer study showing 34% patients
treated with this drug showed positive response after 6 months of treatment
with this pill. While being treated with Gleeve 33% patient shows positive
result by 48 weeks while 50% of patients showed positive result on administration
of Bosulif without any problem of Leukemia within that period.
The common side effects
seen in the patients are nausea, diarrhea, pain in abdomen, mild fever, and
rash, although none of these side effects are found too acute.
No comments:
Post a Comment